Ratings GSK plc

Equities

GSK

GB00BN7SWP63

Market Closed - London S.E. 11:35:09 2024-06-14 EDT 5-day change 1st Jan Change
1,604 GBX -0.34% Intraday chart for GSK plc -1.50% +10.64%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
  • According to Refinitiv, the company's ESG score for its industry is good.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 11.65 for the current year.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company appears highly valued given the size of its balance sheet.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
+10.64% 82.98B
B
+50.70% 791B
C+
+41.96% 630B
B
-7.15% 350B
C+
+18.77% 328B
B-
+8.79% 298B
C+
+18.02% 246B
B+
+1.27% 225B
A+
+11.95% 218B
B-
+3.68% 160B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes